Updated on 21 February 2015
These patents are said to be valid until 2030
Singapore: The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.
Histaminargic dysfunction has been strongly associated with the cognitive and behavioral deficits observed in several CNS disorders such as Alzheimer's, ADHD, dementia, depression, Huntington's disease and Parkinson's disease.
H3 receptor blockade elevates acetylcholine in brain regions responsible for cognition, thus offer a means for targeting cognitive processes.
Novel, potent, selective, brain penetrant and orally active H3 receptor inverse agonist for the treatment of cognitive deficits would offer new line of treatment for this unmet medical need.With these new patents, Suven has a total of twenty granted patents from Australia, seventeen from Canada, fifteen from Japan and twenty two from New Zealand.
These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.